The results demonstrated that aCD3-aHER2 SMART-Exos exhibited enhanced binding affinity towards both CD3+ and HER2+ cell lines in vitro, mediating the interaction between T cells and HER2+ tumor cells, thereby activating cytotoxic T cells to target HER2-expressing cancer cells effectively. This evidence concerns the gene ERBB2 and neoplasm.